Structure Therapeutics Form 4: CSO Retains 204,327 Shares After Withholding

Rhea-AI Filing Summary

Structure Therapeutics Inc. (GPCR) reporting person Lin Xichen, who serves as Chief Scientific Officer and a director, disclosed a transaction on 07/01/2025 affecting her beneficial ownership. The filing shows 12,846 ordinary shares were disposed of through withholding to satisfy income tax obligations tied to the vesting of a restricted share unit award; the per‑share price reported for that disposition was $6.8366.

After the withholding transaction, Lin Xichen beneficially owns 204,327 ordinary shares, held directly. The filing notes that the company’s ordinary shares may be represented by ADSs, with each ADS equal to three ordinary shares. The form is a routine Section 16 report itemizing an insider tax‑related share withholding.

Insights

Securities Analyst

TL;DR: Routine insider tax withholding reduced shares by 12,846; remaining direct stake is 204,327 shares.

This Form 4 documents a standard tax withholding event tied to RSU vesting rather than an open‑market sale. The disposal of 12,846 ordinary shares at $6.8366 per share was executed to satisfy income tax obligations. The reporting person retains a material direct holding of 204,327 shares, which suggests continued alignment with shareholder interests. For investors, this is primarily administrative and not indicative of a change in insider conviction.

Corporate Governance Expert

TL;DR: Disclosure is complete for a routine withholding; role as officer and director is reaffirmed.

The filing clearly identifies the reporting person as Chief Scientific Officer and director and provides the transaction date and mechanics (withholding to satisfy taxes on RSU vesting). The inclusion of ADS representation clarifies share class treatment. As a governance matter, timely Section 16 reporting and transparent explanation of the withholding support compliance standards; there is no evidence in the filing of discretionary insider selling beyond tax withholding.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lin Xichen

(Last) (First) (Middle)

C/O STRUCTURE THERAPEUTICS INC.

601 GATEWAY BLVD., SUITE 900

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Structure Therapeutics Inc. [ GPCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF SCIENTIFIC OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	07/01/2025		F		12,846(2)	D	$6.8366	204,327	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents three Ordinary Shares of the Issuer.

2. Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a restricted share unit award.

	/s/ Jun Yoon, Attorney-in-Fact	08/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Lin Xichen (GPCR) report on the Form 4 filed for 07/01/2025?

The Form 4 reports that 12,846 ordinary shares were disposed of via withholding to satisfy income tax obligations tied to RSU vesting; 204,327 shares remain beneficially owned directly.

Why were shares disposed of according to the Form 4 for GPCR?

The filing explains the disposition represents shares withheld by the issuer to satisfy income tax obligations associated with the vesting of a restricted share unit award.

At what price were the shares withheld in the GPCR Form 4?

The reported per‑share price for the withholding transaction was $6.8366.

What is the reporting person's role at Structure Therapeutics (GPCR)?

The reporting person, Lin Xichen, is listed as Chief Scientific Officer and a director of Structure Therapeutics Inc.

Does the Form 4 indicate the company uses ADSs for its ordinary shares?

Yes. The filing notes that ordinary shares may be represented by American Depositary Shares (ADSs), with each ADS representing three ordinary shares.